Syringe system

• US 5,984,906 A
• Filed: 02/03/1997
• Issued: 11/16/1999
• Est. Priority Date: 07/12/1991
• Status: Expired due to Fees

• Current Assignee: Novo Nordisk A/S
• Original Assignee: Novo Nordisk A/S
• Inventors: J.o slashed.rgensen, Peter Nissen, Bonnichsen, Frits Frydendal
• Primary Examiner(s): YASKO JR, JOHN D
• Application Number:
  US08/794,026
• Time in Patent Office: 1,016 Days
• Field of Search: 604/272, 604/239, 604/232, 604/273, 604/274, 604/51, 604/52
• US Class Current: 604/272
• CPC Class Codes: A61K 38/28 Insulins
• CPC Class Codes: A61M 5/32 Needles; Details of needles pertaining to their connection with syringe or hub infusion needles A61M5/158; Accessories for bringing the needle into, or holding the needle on, the body A61M5/42, A61M5/46 take precedence; guide needles for catheters A61M25/065; Devices for protection of needles apparatus specially adapted for cleaning or sterilising needles A61M5/001
• CPC Class Codes: A61M 5/46 having means for controlling depth of insertion

Abstract

An insulin injection system comprises a pen shaped syringe with a cartridge containing insulin, and an injection needle. The needle is a G30 needle and the insulin is a type which may freely flow through a G 30 needle. When the insulin is the type comprising suspended crystals the maximal dimension of any crystal is 15 μm.

Claims

1. An insulin injection system comprising a pen shaped syringe comprising a cartridge with insulin and an injection needle, wherein the needle is thinner than a G-29 needle and the cartridge contains an insulin type which may freely flow through a needle thinner than a G-29 needle.

2. An insulin injection system according the claim 1, wherein the insulin type in the cartridge has a maximal crystals size of 15 μ

m.

3. An insulin injection system according to claim 1, wherein the pen shaped syringe is a disposable device prefilled with insulin.

4. An insulin injection system according to claim 1, wherein the pen shaped syringe is a durable device designed to receive only cartridges containing insulin which may pass freely through a thinner than G-29 needle.

5. An insulin injection system according to claim 1, wherein the needle has attaching means for cooperation with attaching means on the pen shaped syringe.

6. An insulin injection system according to claim 5, wherein the needle attaching means is a needle hub having a thread cooperating with a corresponding thread on the pen shaped syringe.

7. An insulin injection system according to claim 6, wherein the needle hub has a central protrusion covering part of the length of the needle.

8. An insulin injection system according to claim 7, wherein the length of the injection part of the needle is 8-12 mm.

9. An insulin injection system according to claim 2, wherein the pen shaped syringe is a disposable device prefilled with insulin.

10. An insulin injection system according to claim 2, wherein the pen shaped syringe is a durable device designed to receive only cartridges containing insulin which may pass freely through a thinner than G-29 needle.

11. A needle assembly comprising:

(a) a needle hub having a base and a standard insulin needle fitting for removably mounting said needle assembly on a pen-type insulin syringe having a standard mounting and which accepts cartridges containing only insulin types that may flow freely through a thinner than G-29 needle; and

(b) a thinner than G-29 needle secured in said base and having first and second needle portions extending from said base in opposite directions.

12. A needle assembly according to claim 11, wherein said standard fitting includes an annular sleeve extending from said base such that said sleeve surrounds said first needle portion concentrically and is spaced therefrom, and wherein said sleeve has a threaded interior by which it may be screwed onto a standard, externally threaded, hub-receiving part of a pen-type insulin syringe.

13. A needle assembly according to claim 12, and wherein said second needle portion has a predetermined length appropriate for injecting insulin into a human patient.

14. A needle assembly according to claim 13, wherein said base further comprises a central protrusion which extends from said base for a predetermined distance along said second needle portion and embeds said second needle portion along the said distance, and wherein said second needle portion further comprises an exposed end which projects axially from said central protrusion and which has a length corresponding to the desired depth of needle insertion into a human patient.